Heron Therapeutics (HRTX) EBIT Margin (2010 - 2026)
Heron Therapeutics (HRTX) reported EBIT Margin of 13.73% for Q1 2026, down 2183.0% on a YoY basis from 0.66% in Q1 2025, and down 14762.56% quarter-over-quarter from 0.09% in Q4 2025.
Heron Therapeutics (HRTX) EBIT Margin (2010 - 2026) Analysis & Trends
Heron Therapeutics has reported EBIT Margin for 12 years, with the latest figure at 13.73% in Q1 2026.
- For the quarter ending Q1 2026, EBIT Margin fell 2183.0% year-over-year to 13.73%; the trailing twelve-month figure through Mar 2026 stood at 6.94% (down 453.0% YoY), and the FY2025 full-year result was 1.64%, up 635.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 13.73%, down from 0.09% in the prior quarter.
- The five-year high for EBIT Margin was 10.23% in Q4 2024, with the low at 268.25% in Q1 2022.
- Historically, EBIT Margin has averaged 63.7% across 5 years, with a median of 17.89% in 2024.
- Annual changes were most pronounced in 2022 — EBIT Margin surged 19141 bps — and 2026, when it tumbled 2183 bps.
- Heron Therapeutics' EBIT Margin stood at 67.79% in 2022, then soared by 56 bps to 29.85% in 2023, then surged by 134 bps to 10.23% in 2024, then plunged by 99 bps to 0.09% in 2025, then plunged by 14763 bps to 13.73% in 2026.
- The last three EBIT Margin figures came in at 13.73% (Q1 2026), 0.09% (Q4 2025), and 10.71% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Heron Therapeutics | 85.57 Mn | 55.60 Mn | 24.07 Mn | -13.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.73% |
| Dec 31, 2025 | 0.09% |
| Sep 30, 2025 | -10.71% |
| Jun 30, 2025 | -4.40% |
| Mar 31, 2025 | 8.11% |
| Dec 31, 2024 | 10.23% |
| Sep 30, 2024 | -13.59% |
| Jun 30, 2024 | -17.89% |
| Mar 31, 2024 | -13.84% |
| Dec 31, 2023 | -29.85% |
| Sep 30, 2023 | -79.31% |
| Jun 30, 2023 | -133.50% |
| Mar 31, 2023 | -111.64% |
| Dec 31, 2022 | -67.79% |
| Sep 30, 2022 | -157.71% |
| Jun 30, 2022 | -179.15% |
| Mar 31, 2022 | -268.25% |
| Dec 31, 2021 | -259.20% |
| Sep 30, 2021 | -222.59% |
| Jun 30, 2021 | -269.43% |